Evidence map›Paper›PMID 40198787›Full record

ArticleArchives of endocrinology and metabolism2025

New onset diabetes manifesting as diabetic ketoacidosis in a patient with chronic myelogenous leukemia treated with imatinib.

Dinara Salimova, Tatevik Aloyan, Ursula Qureshi, Faisal Qureshi, Hina Wazir

Abstract readCase Reports
In one paragraph

Article in Archives of endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dinara SalimovaAscension St Joseph Hospital, Chicago, IL, USA.ORCID 0000-0001-6024-2069
Tatevik AloyanAscension St Joseph Hospital, Chicago, IL, USA.ORCID 0000-0001-6212-5018
Ursula QureshiKansas City University College of Medicine and Biomedical Sciences, Kansas City, MO, USA.ORCID 0009-0009-5971-3607
Faisal QureshiAscension St Joseph Hospital, Chicago, IL, USA.ORCID 0009-0003-8817-5568
Hina WazirAscension St Joseph Hospital, Chicago, IL, USA.ORCID 0009-0008-0231-3365

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imatinibis a commonly used antiproliferative agent for treating chronic myelogenous leukemia and gastrointestinal stromal tumors, and it is also thought to be effective in other areas, such as rheumatologic diseases. It has been shown to improve glucose control in diabetic patients by lowering blood sugar, reducing HbA1c levels, and decreasing the need for diabetes medications. However, we present a rare occurrence of severe hyperglycemia and newly elevated HbA1c in a patient on imatinib with no prior history of diabetes. It underscores the need for further research to assess the safety and impact of imatinib on glucose metabolism.

Indexed as

Antineoplastic AgentsDiabetic KetoacidosisImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveBlood GlucoseGlycated HemoglobinHumansAntineoplastic AgentsBlood GlucoseGlycated HemoglobinImatinib Mesylate

Identifiers

PMID40198787
PMCPMC11977861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.